Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT

Bone Marrow Transplantation volume 57, pages 416–422 (2022)Cite this article

Subjects

A Correction to this article was published on 31 March 2022

This article has been updated

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for patients with myeloid/lymphoid neoplasm (MLN) with FGFR1 rearrangement, but data on overall results are limited. We report on the largest series of patients (n = 22) with FGFR1-rearranged MLN undergoing allo-HCT. Distribution according to cytogenetic subtype was: t(8;13) in 11 cases, t(8;22) in 7 cases, t(6;8) in 2 cases, and other (n = 2). Over a third of patients displayed a chronic myeloproliferative (MPN) phenotype, another third showed MPN features with concomitant lymphoma or acute leukemia, and the remaining ones presented as acute leukemia. After a median follow-up of 4.1 years from transplant, the estimated 5-year survival rate, progression-free survival, non-relapse mortality and relapse incidence was 74%, 63%, 14% and 23%, respectively. Causes of death were relapse/progression (n = 4), graft-versus-host disease (n = 2) and organ toxicity (n = 1). Six patients experienced disease relapse at a median of 6.1 months (range: 2.3–119.6). Two of them achieved complete remission with ponatinib or pemigatinib and were alive at 34.5 and 37 months from relapse, respectively. These data highlight the significant curative potential of allo-HCT in this aggressive disease. Maintenance with tyrosine kinase inhibitors may be a promising approach, at least in cases with detectable residual disease after transplant.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Change history

References

  1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    Article  CAS  PubMed  Google Scholar 

  2. Patnaik MM, Gangat N, Knudson RA, Keefe JG, Hanson CA, Pardanani A, et al. Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. Am J Hematol. 2010;85:238–42.

    Article  CAS  PubMed  Google Scholar 

  3. Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, et al. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018;59:1672–6.

    Article  CAS  PubMed  Google Scholar 

  4. Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, Cross NC, et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell. 2004;5:287–98.

    Article  CAS  PubMed  Google Scholar 

  5. Inhorn RC, Aster JC, Roach SA, Slapak CA, Soiffer R, Tantravahi R, et al. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood. 1995;85:1881–7.

    Article  CAS  PubMed  Google Scholar 

  6. Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DH, Aguiar RC, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood. 1998;92:1735–42.

    Article  CAS  PubMed  Google Scholar 

  7. Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010;41:461–76.

    Article  CAS  PubMed  Google Scholar 

  8. Macdonald D, Aguiar RC, Mason PJ, Goldman JM, Cross NC. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia 1995;9:1628–30.

    CAS  PubMed  Google Scholar 

  9. Baer C, Muehlbacher V, Kern W, Haferlach C, Haferlach T. Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2. Haematologica. 2018;103:e348–e50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Khodadoust MS, Luo B, Medeiros BC, Johnson RC, Ewalt MD, Schalkwyk AS, et al. Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia. 2016;30:947–50.

    Article  CAS  PubMed  Google Scholar 

  11. Kasbekar M, Nardi V, Dal Cin P, Brunner AM, Burke M, Chen YB, et al. Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. Blood Adv. 2020;4:3136–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Verstovsek S, Subbiah V, Masarova L, Yin CC, Tang G, Manshouri T, et al. Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. Ann Oncol. 2018;29:1880–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Verstovsek S, Vannucchi A, Rambaldi A, Gotlib J, Mead A, Hochhaus A, et al. Interim results from fight-203, a phase 2, open-label, multicenter study evaluating the efficacy and safety of pemigatinib (INCB054828) in patients with myeloid/lymphoid neoplasms with rearrangement of fibroblast growth factor receptor 1 (FGFR1). Blood. 2018;132 :(abstract 690).

  14. Dolan M, Cioc A, Cross NC, Neglia JP, Tolar J. Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion. Pediatr Blood Cancer. 2012;59:194–6.

    Article  PubMed  Google Scholar 

  15. Konishi Y, Kondo T, Nakao K, Asagoe K, Otsuka Y, Nishikori M, et al. Allogeneic hematopoietic stem cell transplantation for 8p11 myeloproliferative syndrome with BCR-FGFR1 gene rearrangement: a case report and literature review. Bone Marrow Transpl. 2019;54:326–9.

    Article  Google Scholar 

  16. Katagiri S, Umezu T, Azuma K, Kobayashi C, Akahane D, Suguro T, et al. Maintenance 5-azacytidine therapy by MRD monitoring after allogeneic HSCT in myeloid/lymphoid neoplasms with FGFR1 rearrangement. Bone Marrow Transpl. 2019;54:1148–50.

    Article  CAS  Google Scholar 

  17. Townsend W, Cross NC, Waghorn K, Somana K, Ramsay A, Thomson K, et al. Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder. Bone Marrow Transpl. 2009;44:197–9.

    Article  CAS  Google Scholar 

  18. Suzan F, Guasch G, Terre C, Garcia I, Bastie JN, Maarek O, et al. Long-term complete haematological and molecular remission after allogeneic bone marrow transplantation in a patient with a stem cell myeloproliferative disorder associated with t(8;13)(p12;q12). Br J Haematol. 2003;121:312–4.

    Article  CAS  PubMed  Google Scholar 

  19. Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. 2001;98:3778–83.

    Article  CAS  PubMed  Google Scholar 

  21. Montenegro-Garreaud X, Miranda RN, Reynolds A, Tang G, Wang SA, Yabe M, et al. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase. Hum Pathol. 2017;65:147–56.

  22. Gupta V, Kennedy JA, Capo-Chichi JM, Kim S, Hu ZH, Alyea EP, et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. Blood Adv. 2020;4:5562–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

JCHB, AP, LG, TC, DM and IYA were involved in study design, analysis and writing of the paper. NZ was the data manager. All other co-authors contributed data to the study, critically revised the paper and approved the submitted and final version.

Author information

Author notes

  1. These authors jointly supervised this work: Juan Carlos Hernández-Boluda and Ibrahim Yakoub-Agha.

Authors and Affiliations

  1. Hospital Clínico Universitario-INCLIVA, University of Valencia, Valencia, Spain

    Juan-Carlos Hernández-Boluda

  2. Hospital Clínic, Barcelona, Spain

    Arturo Pereira

  3. EBMT Data Office Leiden, Leiden, the Netherlands

    Nienke Zinger

  4. EBMT Statistical Unit, Leiden, the Netherlands

    Luuk Gras

  5. Hospital Santa Creu i Sant Pau, Barcelona, Spain

    Rodrigo Martino

  6. Birmingham Heartlands Hospital, Birmingham, UK

    Emmanouil Nikolousis

  7. Medical Center, University of Freiburg, Faculty of Medicine, Freiburg, Germany

    Jürgen Finke

  8. Hospital Ramón y Cajal, Madrid, Spain

    Anabelle Chinea

  9. University of Milan and Azienda Socio Sanitaria Territoriale Ospedale Papa Giovanni XXIII, Bergamo, Italy

    Alessandro Rambaldi

  10. Hôpital Saint-Louis, APHP, Université de Paris, Paris, France

    Marie Robin

  11. Azienda Ospedaliera Universitaria Careggi, Firenze, Italy

    Riccardo Saccardi

  12. Bone marrow Transplant Center, Ospedale Civile, Pescara, Italy

    Annalisa Natale

  13. Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

    John A. Snowden

  14. Attikon University General Hospital, University of Athens, Athens, Greece

    Panagiotis Tsirigotis

  15. Hospital Universitario Donostia, San Sebastian, Gipuzkoa, Spain

    Carlos Vallejo

  16. Universitätsklinikum Göttingen, Göttingen, Germany

    Gerald Wulf

  17. ICO-Hospital Universitari Germans Trias i Pujol, Badalona, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain

    Blanca Xicoy

  18. University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy

    Domenico Russo

  19. University Hospital Gasthuisberg, Leuven, Belgium

    Johan Maertens

  20. Hopital Jean Minjoz, Besancon, France

    Etienne Daguindau

  21. Skanes University Hospital, Lund, Sweden

    Stig Lenhoff

  22. Trinity College Dublin, St. James’s Hospital, Dublin, Ireland

    Patrick Hayden

  23. Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

    Tomasz Czerw

  24. Guys’ and St. Thomas’ NHS Foundation Trust and University College London Hospitals, London, UK

    Donal P. McLornan

  25. CHU de Lille, Université de Lille, INSERM U1286, Infinite, 59000, Lille, France

    Ibrahim Yakoub-Agha

Authors
  1. Juan-Carlos Hernández-Boluda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arturo Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nienke Zinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luuk Gras
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rodrigo Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emmanouil Nikolousis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jürgen Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anabelle Chinea
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Alessandro Rambaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Marie Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Riccardo Saccardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Annalisa Natale
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. John A. Snowden
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Panagiotis Tsirigotis
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Carlos Vallejo
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Gerald Wulf
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Blanca Xicoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Domenico Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Johan Maertens
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Etienne Daguindau
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Stig Lenhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Patrick Hayden
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Tomasz Czerw
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Donal P. McLornan
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Ibrahim Yakoub-Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Juan-Carlos Hernández-Boluda or Ibrahim Yakoub-Agha.

Ethics declarations

Competing interests

All authors declare no competing financial interests. This study was not economically funded. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. This retrospective study was approved by the Chronic Malignancies Working Party (CMWP) of EBMT. Informed consent for inclusion in the EBMT registry was obtained in all patients.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: Two members from that institution collaborated in our study but we didn’t choose the preferred one for the final version of the manuscript. The suggested coauthor is Dr Emmanouil Nikolousis (manos.nikolousis@nhs.net) in place of Shankara Paneesha (shankara.paneesha@nhs.net). Both of them have agreed on this change.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hernández-Boluda, JC., Pereira, A., Zinger, N. et al. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplant 57, 416–422 (2022). https://doi.org/10.1038/s41409-021-01553-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-021-01553-x

This article is cited by

Search

Advanced search

Quick links